{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:39:24Z","timestamp":1792654764246,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.prro.2026.10.005","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:59:22Z","timestamp":1792652362000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two-Year Outcomes of the XXX Trial: Longitudinal Analysis of Safety, PSA Kinetics, and Patient-Reported Outcomes"],"prefix":"10.1016","author":[{"given":"Stefano","family":"Arcangeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9584-637X","authenticated-orcid":false,"given":"Valeria","family":"Faccenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Mombelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Manno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Pisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo Ray","family":"Colciago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Panizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.prro.2026.10.005_bib0001","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.prro.2026.10.005_bib0002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.prro.2026.10.005_bib0003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(25)00656-4","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial","volume":"27","author":"Nilsson","year":"2026","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.prro.2026.10.005_bib0004","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.10.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"issue":"10437","key":"10.1016\/j.prro.2026.10.005_bib0006","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2026.10.005_bib0007","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.10.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110381","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update","volume":"198","author":"Hudson","year":"2024","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.prro.2026.10.005_bib0009","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","article-title":"Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial","volume":"7","author":"Greco","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2026.10.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2026.1886","article-title":"Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial","author":"Zilli","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2026.10.005_bib0011","unstructured":"XXX."},{"key":"10.1016\/j.prro.2026.10.005_bib0012","unstructured":"XXX."},{"issue":"2","key":"10.1016\/j.prro.2026.10.005_bib0013","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.10.005_bib0014","article-title":"Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities","volume":"45","author":"Gomez-Iturriaga","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10.1016\/j.prro.2026.10.005_bib0015","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.prro.2023.08.011","article-title":"Stereotactic Body Radiation Therapy: A Radiosurgery Society Guide to the Treatment of Localized Prostate Cancer Illustrated by Challenging Cases","volume":"14","author":"Ma","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.10.005_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.883725","article-title":"Intrafraction Prostate Motion Management During Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy","volume":"12","author":"Panizza","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.prro.2026.10.005_bib0017","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/cancers15041153","article-title":"Dosimetric Impact of Intrafraction Prostate Motion and Interfraction Anatomical Changes in Dose-Escalated Linac-Based SBRT","volume":"15","author":"Faccenda","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.prro.2026.10.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/mp.18060","article-title":"Real-time monitoring and appropriate margin selection in linac-based prostate SBRT: Analysis of two different intrafraction motion monitoring systems","volume":"52","author":"Panizza","year":"2025","journal-title":"Med Phys"},{"issue":"2","key":"10.1016\/j.prro.2026.10.005_bib0019","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and Management of Testosterone Deficiency: AUA Guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.prro.2026.10.005_bib0020","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.juro.2013.09.040","article-title":"Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice","volume":"191","author":"Chipman","year":"2014","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.prro.2026.10.005_bib0021","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.prro.2026.10.005_bib0022","doi-asserted-by":"crossref","first-page":"P1200","DOI":"10.1016\/j.ijrobp.2025.08.034","article-title":"Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)","volume":"123","author":"Ratnakumaran","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.10.005_bib0023","article-title":"How to optimise prostate SBRT: ESTRO clinical practice consensus recommendations","volume":"22","author":"Draulans","year":"2026","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.prro.2026.10.005_bib0024","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.ijrobp.2025.06.1025","article-title":"Stereotactic Radiotherapy in 3 Fractions for Localized Prostate Cancer","volume":"123","author":"Sanguineti","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.10.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial","volume":"181","author":"Ong","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.10.005_bib0026","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2019.03.002","article-title":"Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial","volume":"135","author":"Alayed","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.10.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2025.104029","article-title":"Two Versus Five-Fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial","volume":"51","author":"Romrattaphan","year":"2026","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.prro.2026.10.005_bib0028","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s12885-024-12165-1","article-title":"SABR-Dual: a phase II\/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer","volume":"24","author":"Fredman","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.prro.2026.10.005_bib0029","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ijrobp.2025.05.008","article-title":"HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy","volume":"123","author":"Cooper","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.prro.2026.10.005_bib0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.prro.2026.10.005_bib0031","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.euo.2024.12.015","article-title":"Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials","volume":"8","author":"Udovicich","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2026.10.005_bib0032","unstructured":"Sunnybrook Health Sciences Centre. Improving sexual quality of life-a phase 2 randomized controlled trial of two vs five stereotactic MRI-guided ablative radiotherapy treatments for prostate cancer (iSMART). https:\/\/clinicaltrials.gov\/study\/NCT05600400."},{"issue":"1","key":"10.1016\/j.prro.2026.10.005_bib0033","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12885-023-11430-z","article-title":"A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)","volume":"23","author":"Wolfe","year":"2023","journal-title":"BMC Cancer"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026003280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026003280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:59:25Z","timestamp":1792652365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850026003280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S1879850026003280"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2026.10.005","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-Year Outcomes of the XXX Trial: Longitudinal Analysis of Safety, PSA Kinetics, and Patient-Reported Outcomes","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2026.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}